William T. Abraham M.D., F.A.C.P., F.A.C.C., F.A.H.A., F.E.S.C., F.R.C.P.
The Ohio State University, Columbus, OH, USA

At Ohio State, Dr.Abraham held several leadership positions including an Associate Dean position. As Director ofthe Clinical Trials Management Organization, hemanaged the College of Medicine’snon-cancer clinical and translational research portfolio of more than 1,800 studies. As DivisionDirector, Dr. Abraham developed one of the largest and most successful academic programs ofCardiovascular Medicine in the U.S.Dr. Abraham spends the majority of his clinical time managing heart failurepatients in the outpatient setting.Hisresearch activities focus on elucidating basic mechanisms in heart failure and onclinical drug and device trials in heart failure.

Stefan D. Anker MD, PhD, FESC
Charité Campus Virchow Klinikum, Berlin, Germany

Stefan D. Anker has been Professor of (Tissue) Homeostasis in Cardiology & Metabolism at Charité Berlin, Germany, since June 2017. Prof. Anker has authored more than 900 original papers, reviews, and editorials that are well. For his work, hehas won several prizes and obtained a number of fellowships and grants.Prof. Anker was Vice President of the European Society of Cardiology (ESC, 2016-18), serving on the ESC board from 2012 to 2018. He has been serving on the board of the Heart Failure Association (HFA) of the ESC since 2006 and was HFA President from 2012 to 2014). He currently chairs the HFA committee on regulatory affairs. He is founding Editor-in-Chief of the first open-access heart failure journal, ESC Heart Failure. Prof. Anker has served on several ESC Guideline task forces.

George L. Bakris MD,F.A.H.A., F.A.S.N.
University of Chicago Medicine, Chicago, IL, USA

Dr.Bakris is a Professor of Medicine and Director of the Am. Heart Assoc. Comprehensive Hypertension Center at the University of Chicago Medicine. He has published over 800 peer-reviewed articles and book chapters in diabetic kidney disease, hypertension,and nephropathy progression. He is the Editor or Co-Editor of 21books in the areas of Diabetic Kidney Disease Progressionand Hypertension. He is Editor of3rd edition of Hypertension: ACompanion to Braunwald’s The Heart,and served on many national guideline committees. Dr. Bakris is the past-president of the American College of Clinical Pharmacologyand the American Society of Hypertension (ASH)

Nisha Bansal MD MAS
University of Washington (UW),Seattle, WA USA

Dr. Nisha Bansalis an Associate Professor and the Arthur StachFamily Endowed Professor in the Division of Nephrology at the University of Washington (UW) in Seattle, WA USA. She is also an investigator in the Kidney Research Institute, the Associate Fellowship Program Director and the Director of the Kidney-Heart Service at UW. Dr. Bansal’s research has advanced the understanding and treatment of cardiovascular disease among the high-risk and growing population of patients with chronic kidney disease, for whom cardiovascular disease remains the leading cause of morbidity and mortality. Her research program consists of clinical, patient-oriented studies to understand the pathophysiology, diagnosis and treatment of hypertension, cardiac arrythmias and heart failure in patients with chronic kidney disease and those treated with dialysis.

Harvard Medical School, Boston, MA, USA

Dr. Deepak L. Bhatt,is Executive Directorof Interventional Cardiovascular Programsat Brigham and Women’s Healthand Professor of Medicine at Harvard Medical School.Dr.Bhatt’s research interests include acute coronary syndromes, preventive cardiology, and advanced techniques in cardiac, cerebral, and peripheral intervention. He has authored or co-authored over 1600 publications.He wasthe international PIfor the CHARISMA andCRESCENDO trials and co-PIof the three CHAMPIONtrials. He served as chair of COGENT and co-PI ofSTAMPEDE. He serves as co-chair of the REACH registryand chairs REDUCE-IT, SOLOIST,and SCORED. He is co-PI of SAVOR-TIMI 53, SYMPLICITY HTN-3,THEMIS, and THEMIS-PCI.

Michael Böhm MD, FESC
University of the Saarland,Homburg/Saar, Germany

Since 2000, Prof. Michael Böhmhas beenDirector of the Klinik für Innere Medizin III and Chief of Cardiology at the University of the Saarland in Homburg/Saar,in Germany. Prof.Böhm’s special interest includes pathophysiology and therapy of heart failure. In particular, he is involved in studies on signal transduction in the failing heart and in vascular biology. Prof.Böhm has been the principal investigator in several international multicentrestudies.He has written more than 500original papers, book chapters and review articles. He has obtained several awards of scientific societies. Professor Böhm is a reviewer for most recognized scientific journalsin the cardiovascular field and chief editor for Clinical Research in Cardiology.He is past-president of the German Society of Cardiology and pastscientific program committee chairman of the European Society of Cardiology.


Biykem Bozkurt MD, PhD, FACC, FAHA
Baylor College of Medicine, Houston, TX, USA

Dr. Biykem Bozkurt is the Medical Care Line Executive (Medicine Department Chair) at the DeBakey VA Medical Center; W.A. “Tex” and Deborah Moncrief, Jr., Chair; Mary and Gordon Cain Chair and Professor of Medicine; and Vice-Chair of Department of Medicine; Director of the Winters Center for Heart Failure and Associate Director of Cardiovascular Research Institute at Baylor College of Medicine. Dr. Bozkurt is an advanced heart failure and cardiac transplantation specialist, with active participation in clinical practice, research and education. She has and continues to participate in numerous national and international scientific sessions as a chair, presenter or a panel discussant

Javed Butler MD, MPH, MBA
University of Mississippi, Jackson, MS, USA

Javed Butleris the Patrick H. Lehan Chair in Cardiovascular Research,and Professor and Chairman of the Department of Medicine at the University of Mississippi. He is also Professor of Physiology. He had served as the director for heart failure research at Emory University and director of the heart and heart-lung transplantprograms at Vanderbilt University prior to that.Dr. Butler is board certifiedin cardiovascular medicineandadvanced heart failure and transplant medicine. His research interests focus on clinical trials in patients with heart failure. He serves on several national committees for the American College of Cardiology, American Heart Association, National Institutes of Health, and the Heart Failure Society of America

David M. Charytan MD, MSc
New York University School of Medicine, New York, NY, USA

David Charytanis the Director of the Division of Nephrology and the Norman S WiklerAssociate Professor of Medicine at New York University School of Medicine. In additionto maintaining a broadclinical practice in general nephrology, heis an active researcher with a focus ondiabetic kidney disease andcardiovascular disease in the setting of chronic kidney disease. Dr.Charytan has served as the principal investigator on multiple NIH and foundation grants and has served as a founding Steering Committee member of the NIH Hemodialysis Novel Therapies (trial) Consortiumwhere he servedas the lead PI of two of the network’s, first fourtrials. Currently, he is also the national lead on two international trials of novel therapies for the treatment of diabetic kidney diseases.

David Cherney
University of Toronto, Toronto, Ontario, Canada

David Cherney is currently Professor of Medicine in the Department of Medicine, University of Toronto and a Clinician Scientist at the University Health Network and Mount Sinai Hospitals, Toronto, where he is also Director of the Renal Physiology Laboratory. Following his clinical training in nephrology, Dr Cherney completed his PhD in human renal physiology at the Institute of Medical Science, University of Toronto in 2008. Dr.Cherney’s research program focuses on physiological factors that initiate renal disease in patients with diabetes, such as renal hyperfiltration and inflammation, and the role of the cardio–renal axis in diabetes. His research group is also involved in early-and late-phase clinical trials in the cardio–renal–metabolic field, including several primary renal outcomes trials in patients with and without diabetes.

John G. F. Cleland, MD, PhD, FRCP, FACC, FESC
Robertson Centre for Biostatistics and Clinical Trials, University of Glasgow, Glasgow, UK

Professor Cleland was appointed the Director of the Robertson Centre for Biostatistics and Clinical Trials in 2016, an internationally accredited Clinical Trials Unit offering a complete service both to academic clinicians and industry. The special area ofexpertise is cardiovascular disease but includes all branches of medicine and social sciences. His main area of interest is in heart failure, extending from its epidemiology and prevention, to Phase II-IV randomized trials through to the development and implementation of guidelines. Particular current interests include the influence of myocardial substrate on therapeutic response, congestion and inflammation as novel therapeutic targets, telemonitoring and theranostics.

Andrew J. S. Coats DM, DSc, MBA, AO
University of Warwick, Coventry, UK and Monash University, Melbourne, Australia

Prof. Andrew Coatshas published over 20 patents and more than over 650 peer-reviewed research papers. He has more than 100,000 career citations, and a personal H-index of 135.Heis an expert on heart failure. He first described the Muscle Hypothesis of Chronic Heart Failure that explained dyspnoea and exaggeratedventilatory responses in CHF patients. He first described chemoreflex overactivity in CHF and periodic breathing and published the first ever randomised trial of exercise training for CHF.He has served as Head ofCardiology at Imperial College and Director of Cardiology at Royal Brompton Hospital, London then as Dean of Medicine and DeputyVice-President at the University of Sydney, and as Joint Academic Vice-President of Monash University, Australia and the University of Warwick, UK. He is President of the Heart Failure Association of the ESC.

Mark E. Cooper AO, MB BS, PhD, FRACP, FAHMS
Central Clinical School, Monash University, Melbourne VIC, Australia

Mark Cooper is the inaugural Head of the Department of Diabetes, Central Clinical School, Monash University.He was previously the Chief Scientific Officer of the Baker IDI Heart & Diabetes Institute as well as the Director of the Juvenile Diabetes Research Foundation Centre(JDRF) for Diabetes Complications. He is a trained endocrinologist with an appointment at the co-located Alfred Hospital. Dr Cooper is currently Co-Chair of the JDRF Medical Science Review Committee (Complications Panel). He is regularly invited to international meetings and has over 500 peer reviewed publications. Dr Cooper was the 2016 recipient of the Claude Bernard Award from the European Association for the Study of Diabetes and in 2017 the Edwin Bierman Award from the American Diabetes Association. He received an Order of Australia (Officer) in 2017.

Maria Rosa Costanzo, MD
Advocate Heart Institute, Naperville, IL, USA

Dr. Costanzo is a Fellow of the American College of Cardiology, American Heart Association and European Society of Cardiology.She is also a member of the Ordine Dei Medici (The ItalianNational Medical Professional Association. In 2002 Dr. Costanzo became the Medical Director of the Edward Center for Advanced Heart Failure.Dr. Costanzo has ledseveral multicenter randomized clinical trials including UNLOAD, AVOID-HF and the Pivotal Trial of phrenic nerve stimulation for central sleep apnea.Dr. Costanzo was appointed as Associate Editor of the JACC Heart Failure Journal in March, 2020.Dr. Costanzo is currently the Medical Director for Heart Failure Research at the Advocate Heart Institute.

Kevin Damman MD, PhD, FHFA,
University Medical Center Groningen, Groningen, The Netherlands

Since 2015, Dr Kevin Dammanis a clinical cardiologist, head of the heart transplant and ventricular assist device program at the University Medical Center Groningen. As such his field of interest included advanced and acute heart failure. Current research interests are focused on improving treatment of acute heart failure patients, including early assessment of effect of decongestive therapies, SGLT2-inhibition in (acute) heart failure and the roleof the kidney in the process of cardiorenal interaction. He is principalinvestigatorof the EMPA-RESPONSE-AHF study on empagliflozin in acute heart failure and is part of the steering committee of the ADVOR trial investigating acetazolamide in acute heart failure. Dr Damman is associate editor of the European Journal of Heart Failure and is member of the working groups on Cardiorenal Dysfunction, Advanced Heart Failure and Acute Heart Failure from the Heart Failure Association of the ESC

Lori B. Daniels MD, MAS, FACC, FAHA
University of California, San Diego,La Jolla, CA, USA

Dr.Daniels is a Professor of Medicine and Cardiologist at the University of California, San Diego,where she is the MedicalDirector of the CardiovascularIntensive Care Unit. She received a Masters of Advanced Studies in Clinical Research, and is a Fellow of the American College of Cardiologyand of the American Heart Association.Dr. Daniels isthe recipient of multiple national grants studying cardiovascular epidemiology, women’s cardiovascular health, and cardiovascular biomarkers.Her research interests focus on cardiovascular epidemiology(including in COVID-19), biomarkers,critical care cardiology, cardiovascular outcomes in young adults with a childhood history of Kawasaki Disease, and imaging in chronic thromboembolic pulmonary hypertension.

Melanie Davies CBE, MB ChB,MD,FRCP,FRCGP, FMedSci
University of Leicester, Leicester, United Kingdom

Melanie J.Davies is Professor of Diabetes Medicine at the University of Leicester and an Honorary Consultant Diabetologist at the University Hospitals of Leicester NHS Trust. She is based in the Diabetes Research Centre, University of Leicester and is also the Co-Director of the Leicester Diabetes Centre, University Hospitals of Leicester NHS Trust. Professor Davies’ research interests include the causes, screening, prevention, self-management and treatment of type 2 diabetes mellitus. She is a National Institute for Health Research Senior Investigator Emeritus and Director of the NIHR Leicester Biomedical Research Centre. Professor Davies is the Principal Investigator on a number of large global studies in the field of diabetes, obesity, physical activity, sedentary behaviour and cardiovascular disease and co-chair of EASD/ADA’s Consensus Report on T2DM Management.

Prof. Fausto J. Pinto MD, PhD, FESC, FACC, FSCAI, FASE
Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal

Prof. Fausto J. Pinto is currently the Dean of the Faculty of Medicine of the University of Lisbon, and Full Professor of Cardiology, Head of the Cardiology Department and of the Heart and Vascular Department of Santa Maria University Hospital, CHULN E.P.E., President Elect of the World Heart Federation (WHF) (2019-2020), National Coordinator of the Medical Schools Council (2018-2020) and President of the Executive Board of the Lisbon Academic Medical Centre (CAML) (2019-2021) and Director of Lisbon Cardiovascular Institute (ICVL) since 1999.His main areas of interest are ischemic heart disease, anticoagulation, cardiovascular imaging, particularly on the use of ultrasound in cardiology and pioneered the use of intravascular ultrasound in the study of graft atherosclerosis. Read more

Gerasimos Filippatos, MD, FESC, FHFA, FACC, FCCP
University of Cyprus & National and Kapodistrian University of Athens, Athens, Greece

Gerasimos Filippatos is currently Dean, of the School of Medicine, and Professor of Cardiology,at the University of Cyprus & National and Kapodistrian University of Athens, Greece.Prof.Filippatos is past President of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Prof.Filippatos is Associate Editor of the European HeartJournal, International Journal of Cardiologyand Journal of Cardiovascular Medicine.He has published over 450 articles in peer-reviewed journals and authored more than 30 book chapters including the “Acute Heart Failure” chapter in Braunwald’s Heart Diseaseand Oxford Desk Reference: Cardiology.He is Honorary Member of several cardiac societies, namely the French Cardiac Society, Romanian Cardiac Society, and Hungarian Cardiac Society.

Steven Fishbane, MD
Northwell Health,Zucker Hillside Hospital,Glen Oaks, NY,USA

Steven Fishbaneis the Chief of the Division of Medicine –Kidney Diseases and Hypertension at North Shore University Hospital, New York, and at the Long Island Jewish Medical Center, New York. He is also a Physician and researcher at Northwell Health and a Professor of Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.Prof.Fishbane’s research interests focus on complications of kidney disease, anaemia, iron management, outcomes of kidney disease, hypertension, kidney stones and kidney failure.

Marat Fudim MD, MHS
Duke University,Duke Clinical Research Institute, Durham, NC, USA

Marat Fudimis an Assistant Professor of Medicine at the Duke University Medical Center and the Duke Clinical Research Institute. His clinical practice includes heart failure, mechanical circulatory support and heart transplantation. His research focus is on the pathophysiology of heart failure and the role of the autonomic nervous system, the mechanisms of vascular congestion and the investigation of novel treatments for acute and chronic heart failure.

Jennifer B. Green MD
Duke University,Duke Clinical Research Institute, Durham, NC, USA

Dr. Jennifer Green is a professor of medicine in the division of endocrinology, metabolism, and nutritionat Duke University and a faculty member of the Duke Clinical Research Institute. Her work with the DCRI has included protocol development, oversightof adjudication committees, and clinical and operational leadership for several large, international trialsdesigned to determine the cardiovascular effects ofglucose-lowering medications (TECOS, EXSCEL, andHarmony Outcomes). She currently serves as US coordinating center PI and US national representativefor the EMPA-Kidney trial of empagliflozin therapy in patients with chronic kidney disease. Dr. Green isalso a member of the American Diabetes Association’s Professional Practice Committee, which publishesthe organization’s annual Standards of Care in Diabetes

Yehuda Handelsman MD, FACP, FNLA, FASPC, MACE
Tarzana, CA, USA

Dr.Yehuda Handelsman is an endocrinologist in private practice and Medical Director & Principal Investigator of the Metabolic Institute of America. He is a nationally and internationally recognized authority on Diabetes, Lipids, Obesity, HTN their management and the prevention of complications-specifically ASCVD, HFand CKD. He is Master of American College of Endocrinology, Fellow American Society of Preventive Cardiology,National lipid Association and the American College of Physicians. Hechaired theAACE/ACE2020Lipid management Algorithmto Prevent cardiovascular disease, a Member of AACE/ACE 2020 Comprehensive Diabetes Management AlgorithmandCombined Guidelines for CGM & Pumps. He published over140peer reviewed original research,practice guidelines,editorialsand books’ chapters.

Hao, Chuan-Ming,

The President, Chinese Society of Renal Physiology
Standing Committee Member, Chinese Society of Nephrology
Committee member, CME committee, Asian-Pacific Society of Nephrology
Committee member, The best practice recommendation committee, Asian-Pacific Society of Nephrology
Member of ISN
Active member of ASN
Committee member, Nominating committee, ASN (2018)
Fellow of the ASN
Regular member of American Physiological Society
read more

Gerd Hasenfuß MD,FESC, FAHA, FISHR

Gerd Hasenfuß is Professor of Internal Medicine and Cardiology and is Directorof the Clinic of Cardiology and Pneumology at University Medical Center Göttingen, Germany(since1998),Chair of Heart Center Göttingen(since 2001), and of HRCG(since 2010).Dr. Hasenfuß received his training in medicine at University of Freiburg from 1982 to 1988. From 1988 to 1990 he was Visiting Assistant Professor at Department Molecular Physiology and Biophysics, University of Burlington, Vermont, USA. 1993 to 1998 he was an Assistant Professor in Internal Medicine and Cardiology, University of Freiburg.He is a regular member of the Academy of Science in Göttingensince 2002, and since 2019 he is a member of German National Academy of Sciences Leopoldina. Read more

Adrian Hernandez MD, MHS
Duke University School of Medicine, Duke Clinical Research Institute, Durham, NC, USA

Adrian Hernandez, is Executive Director,Duke Clinical Research Institute,and also serves as Vice Dean and Professor of Medicine, Division ofCardiology,at the Duke University School of Medicine, all in Durham, NC. Dr. Hernandez has research interests in the cardiology field, specifically acute, chronic, and advanced heart failure, heart failure and comorbidities, quality of care and outcomes research, clinical trials, comparative effectiveness and health policy. Dr. Hernandez is a member of the American College of Cardiology, the American Heart Association, the Heart Failure Society of America, and the American Society for Clinical Investigation. He has co-authored more than 600peer-reviewed publications.

Charles A. Herzog MD, FACC, FAHA
University of Minnesota, Minneapolis, MN, USA

Dr. Charles Herzog isprofessor of medicine, University of Minnesota,and cardiologist at Hennepin County Medical Center (HCMC)/Hennepin Healthcarefor37years. He founded the program in interventional cardiology at HCMC and served ascardiac catheterization laboratory director from 1985-1991,andcardiac ultrasound laboratory director from 1997-2012. He wasdirector of theUnited States Renal Data System (USRDS)Cardiovascular Special Studies Center from 1999-2014. He participated in the development ofthe National Kidney Foundation’s K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients andKDIGO Clinical Practice Guidelines on Acute Kidney Injury, and the KDIGO 2017 Clinical Practice Guidelines Update for CKD-Mineral and Bone Disorder.

James L. Januzzi
Harvard Medical School,Boston, MA, USA

Dr. James Januzzi is currently the Hutter Family Professor of Medicine at Harvard Medical School. Dr. Januzzi’sresearch work has contributed greatly to the understanding of cardiac biomarker testing, where his studies have set international standards for use in diagnosis, prognosis, and management of patients suffering from acutely decompensated heart failure, chronic heart failure as well as those with acute coronary syndromes. He is also an experienced clinical trialist with a focus on drug therapy for heart failure, diabetes drugs, and anti-thrombotics.Dr. Januzzi has published more than 650 manuscripts, book chapters, and review articles, and has edited six textbooks..

Dr Sanjay Kalra

DM Endocrinology, AIIMS New Delhi, FRCP (Edin)
Consultant, Bharti Hospital, Karnal
Visiting Professor, AIIMS, Rishikesh
Immediate Past President, Endocrine Society of India (ESI)
Vice President, South Asian Federation of Endocrine Societies (SAFES)
Education Editor, International Society of Endocrinology (ISE)
Read more

Mikhail Kosiborod MD, FACC, FAHA
University of Missouri-Kansas City,Kansas City, MO, USA

Dr. Mikhail Kosiborod is a cardiologist, the Vice President of Research at Saint Luke’s Health System, Executive Director of the Cardiometabolic CenterAlliance, Director of Cardiometabolic Research and Co-Director of the Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid America Heart Institute, and Professor of Medicine at the University of Missouri-Kansas City. Heis an internationally recognized expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes, as well as quality of care and outcomes. Dr. Kosiborod has authored and co-authored over 220 peer-reviewed publications, including scientific statements and position documents. Heis involved in the leadership of multiple clinical trials and multi-center registries, and is currently the principal investigator of several investigator-initiated, multicenter trials in diabetes and cardiovascular disease.

Adeera Levin MD, FRCPC
Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada

Dr. AdeeraLevin is a Professor of Medicine, Head Division of Nephrology at the University of British Columbia, and Consultant nephrologist at Providence Health Care/ St Paul’s Hospital, in Vancouver Canada. She has been appointed Sr Medical Lead, Integration Clinical and Academic Networks at PHC. She is the Executive Director of the BC Renal Agency, which oversees the care, planning and budgets for Kidney services in the province of British Columbia.Her major research interests include CVD in CKD patients, variability in the progression of CKD and optimalmodels of care.She has over 300 peer reviewed publications,andnumerous book chapters.She is the Principal Investigator on a patient orientednetwork grant CAN SOLVE CKD.

Cecilia Linde MD
Karolinska University Hospital, Stockholm, Sweden

Dr. Cecilia Linde is Professorand consultant in Cardiology at the Heart and Vascular Theme at the Karolinska University Hospitalin Stockholm, Swedenand the Karolinska Institutet. Her researchcurrently focusesdevicesand epidemiology in heart failure. She was co-chairman in the MUSTIC study,principal investigator of the REVERSEstudy, which was to first to show a benefit of CRT in mild heart failureand the MIRACLE-EF studyfocusing onCRT in HFmREF. She chairs theStockholm PREFERS studies with Associate Professor Hans Persson. PREFERS focuseson epidemiology,imaging and biomarkers in new onset heart failure with special attention to HFpEFand on the transition from hypertensionto heart failure in the search of new drug targets.Sheis co-PI of the European CRT surveyIIcovering 10.088CRT implantationsacross 42 European countrieswith Professor KennethDickstein, Stavanger,Norway.

JoAnn Lindenfeld, MD
Director, Heart Failure and TransplantProfessor of Medicine Vanderbilt
University School of MedicineNashville, TN

JoAnn Lindenfeld, MD, began her career investigating the role of anemiain the regulation of cardiac output, which subsequently led her to develop the heart failure and transplant program at the University of Colorado. She has extensive experience in the direction and oversight of large multicenter randomized clinical trials in heart failure, heart transplantation, and mechanical circulatory support and has served on steering committees, data and safety monitoring committees, and end point committees of numerous national and international multicenter trials. Dr. Lindenfeld is currently a member of the steering committee for four national and international trials, including COAPT, FIX-HF, Parachute, and CAT-HF. She has served on the FDA Cardiorenal Advisory Panel for 8 years, the Cardiovascular Devices Panel for 4 years, and continues to be an ad hoc member of both panels. Read More

Gregory Y H Lip MD
Liverpool Centre for Cardiovascular Science at the University of Liverpool and Liverpool Heart & Chest Hospital, United Kingdom

Professor Lip, MD, is Price-Evans Chair of Cardiovascular Medicine, at the University of Liverpool, UK –andDirector of the Liverpool Centre for Cardiovascular Science at the University of Liverpool and Liverpool Heart & Chest Hospital.He is also Distinguished ProfessoratAalborg University, Denmark; Adjunct Professor atYonsei Universityand SeoulNational University, Seoul, Korea.He also holds Visiting or Honorary Professorships invarious other Universities in UK, Serbia(Belgrade), China(Beijing, Nanjing, Guangzhou), Thailand(Chiangmai)andTaiwan (Taipei).Half of his time is spent as a clinical cardiologist, including outpatient clinics(leading atrial fibrillation and hypertension specialist services)and acute cardiology

Prof. Iain Macdougall

Professor Macdougall was appointed as a Consultant Nephrologist at King’s College Hospital in London, UK in January 1996, and received his academic promotion to Professor of Clinical Nephrology through King’s College London in March 2011.His sub-specialty interest is the anemia associated with chronic kidney disease, for which he is internationally renowned. He was previously the R&D Lead for the Renal Department at King’s, as well as the South London Renal CLRN lead for the UK NIHR network, and received an NIHR Senior Investigator award for research excellence in 2017.With his research team, he has led or conducted several key multicenter clinical trials, which have shaped the management of renal anemia worldwide, including CREATE,TREAT, FIND-CKD, and PIVOTAL. He has had frequent invitations to lecture both nationally and internationally, and was part of the Work Group for KDIGO in creating the latest clinical practice guideline for the management of anemia in chronic kidney disease. Read more


Kieran McCafferty
Queen Mary, University of London, London, UK

Kieran McCafferty is the Deputy Clinical Director of Research and Development at Barts Health NHS Trust, Queen Mary University of London (QMUL). He is also a physician at QMUL in the nephrology department. Dr McCafferty’s research interests include diabetic kidney disease, hemodialysis, and hypertension.

John McMurray BSc (Hons) MB ChB (Hons) MD FRCP FESC FACC FAHA FRSE FMedSci
Institute of Cardiovascular & Medical SciencesUniversity of Glasgow, UK

Professor John McMurray is graduated from Manchester University with Bsc(Hons) in 1980 and MB ChB (Hons) in 1983. He undertook a period of postgraduate research at the University of Dundee, with award of his research MD in 1990. Then he trained in Medicine and Cardiology in Manchester, Edinburgh, Dundee and Glasgow and was appointed as Consultant Cardiologist in Edinburgh in 1993, before moving to Glasgow in 1995.He is now Professor of Medical Cardiology and Deputy Director of the Institute of Cardiovascular and Medical Sciences at the University of Glasgow, UK and honorary Consultant Cardiologist at the Queen Elizabeth University Hospital, Glasgow. Read more

Milton Packer MD
Distinguished Scholar in Cardiovascular Science at Baylor University Medical Center at Dallas

Dr. Packer is an internationally recognized clinical investigator who has made many seminal contributions to the field of heart failure, both in understanding its mechanisms and defining its rational management. His work has spanned more than40 years and has been strongly supported by numerous investigator-initiated grants from the National Institutes of Health and from industry. Dr.Packer’s research established the cornerstone of the current modern treatments for heart failure, including ACE inhibitors, beta-blockers and angiotensin neprilysin inhibitors. He was also instrumental in raising concerns about the use of positive inotropic agents, calcium channel blockers and antiarrhythmic drugs in patients with left ventricular systolic dysfunction. In recognition of these achievements, he received the Lewis Katz Lifetime Achievement Award from Columbia University College of Physicians and Surgeons. Dr. Packer graduated from Pennsylvania State University and received his medical degree from Jefferson Medical College in 1973, completed his residency in internal medicine at Bronx Municipal Hospital Center in 1976 and his fellowship in cardiology at Mount Sinai School of Medicine in 1978. Read more

Prof.Vlado Perkovi

Scientia Professor Vlado Perkovic is the Dean of Medicine and Health at the University of New South Wales in Sydney, Australia, an active clinician and a leading clinical trialist. Prior to commencing his currentrole in 2019, Professor Perkovic was Executive Director of The George Institute, Australia. He is a part time (0.1 FTE) Staff Specialist in Nephrology at the Royal North Shore Hospital. His research focus is onclinical trials and epidemiology, in particular in preventing the progression of kidney disease and its complications. He has served on the Steering Committees of a large number of international clinical trials including some that have completed-CREDENCE (Chair), TESTING (Chair), CARMELINA (Co-Chair), SONAR and CANVAS-and several that are ongoing-FLOW (Chair), ZEUS (Co-Chair), ASPIRED (Co-Chair), RESOLVE, and TRACK. Read more

Mark Petrie
University of Glasgow, Glasgow, United Kingdom

Mark Petrie is Professor of Cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow, UK, and a Cardiologist at the Golden Jubilee National Hospital and Glasgow Royal Infirmary, Glasgow, UK.Professor Mark Petrie started his studies as an undergraduate in Edinburgh University before training in Cardiology in Glasgow. He worked as a heart failure and interventional cardiologist for many years before transferring to the University of Glasgow in 2016.

Ileana L. Piña, MD, MPH, FAHA, FACC
Wayne State University Detroit, MI, USA

Ileana L. Piña, MD, MPH, is a Professor of Medicine, at Wayne State University and Clinical Professor at Central Michigan University. Dr. Piña also serves as Senior Fellowto the Food and Drug Administrations’ Center for Devices and Radiological Health.Dr. Piña earned her undergraduate degree in chemistry from the University of Miami in Florida. She completed her medical degree and cardiology fellowship at the University of Miami School of Medicine; an internal medicine residency at the University of South Florida Tampa, where she was Chief Resident; and fulfilled a surgery internship at the University of Miami Hospitals and Clinics. She earned a master’s degree in public health from Case Western Reserve University School of Medicine in Cleveland, Ohiowhile pursuing a VA Quality Fellowship. Dr. Piña’s research interests include transition of care in heart failure patients, and the role of natriuretic peptide–guided management for patients hospitalized for heart failure, biomarkers of myocardial stress and fibrosis in chronic heart failure, and heart failure differences by sex. She has been actively involved in gender, racial and ethnic issues in the health care delivery. She is the author/co-author of more than 250 publications.She is currently the Chair of the FIT committee of the AHA and on the Board of Directors National AHA.Dr. Piña is a Senior Staff Fellow and Medical Officer of the FDA, CDRH.

Carol Pollock
The University of Sydney, Camperdown NSW, Australia

Carol Pollock is the Professorial Chair of Medicine at Royal North Shore Hospital, The University of Sydney, Australia. She received her Bachelors of Medicine, specialising in renal medicine, from the University of New South Wales (NSW) and gained her PhD in renal physiology in 1992 from The University of Sydney. Professor Pollock’s main research focuses include nephrology, kidney disease and diabetes, in particular reference to obesity, diabetes and cardiovascular disease, healthy ageing and increasing lifespan.

Prof. Piotr Ponikowski, MD, PhD, FESC, FHFA

Piotr Ponikowski (born in 1961, Wrocław, Poland) is professor of cardiology,Rector and Head of Department of Heart Diseasesat Wroclaw Medical University. He is also Head ofthe Center for Heart Diseasesat University Hospital, Wroclaw, Poland. His research interests focus on the pathophysiology and management of acute and chronic heart failure. He is co-author of more than 700peer-reviewed papers with total number ofcitations: >95000, h-index=117; selected among Highly Cited Researchers by Thomson Reuters 2016, 2017, 2018, 2019. Professor Ponikowski currently serves as Member of the Board of the Heart Failure Association of the European Society of Cardiology (since 2004; in 2010-2012 he served as the President of the Heart Failure Association),former Presidentof the Polish Cardiac Society. Read more

Giuseppe M.C. ROSANO, MD, PHD
Professor of Cardiology,
Consultant Cardiologist, Director MSc Heart Failure

G.R.received his medical degree and his specialisation in cardiovascular medicine from “LaSapienza”University of Rome in Rome, Italy, and his PhD in Medical Sciences from the Imperial College of Science and Technology in London, United Kingdom.G.R. has served as member of the CVWP of the European Medicines Agency since July 2020, he has been board member of the Italian Space Agency and member of the pricing and reimbursement committee at the Italian Drug Agency.G.R.is fellow of the European Society of Cardiology, the Heart Failure Association, the American College of Cardiology, and the Italian Federation of Cardiology. He serves as Editorial Board Member for European Heart Journal, European Journal of Heart Failure, European Heart Journal—Cardiovascular Pharmacotherapy, ESC Heart Failure, Cardiovascular Diabetology, Nature Research Scientific Reports, Cardiovascular Reviews, Advances in Therapy, European Cardiology Review, and Climacteric. G.R.has authored or co-authored more than 500peer-reviewed articles. He is the president-elect of the Heart Failure Association of the ESC.

Patrick Rossignol, MD,PhD
University of Lorraine, Nancy, France

Patrick Rossignol, MD, PhD, is a nephrologist and vascular medicine specialist, European Society of Hypertension-certified hypertension specialist, and Professor of Therapeutics at the University of Lorraine, France. Since 2018, he has been director of the Nancy University Hospital Inserm Clinical Investigation Centre, after serving as its deputy director for ten years. Since 2014, he has beencoordinating a French multidisciplinary (basic researchers, cardiologists, nephrologists, intensivists, epidemiologists, geriatricians) network of excellence endorsed by the French affiliate of ECRIN/ERIC: Cardiovascular and Renal Clinical Trialists (INI-CRCT). He is a researcher at the French National Institute of Health and Medical Research (Inserm U1116), runs outpatient clinics at the University Hospital Heart Failure and Hypertension Unit (ESH excellence centre),as well as in a haemodialysis clinic within adisease management programme(ALTIR). Read more

Dr. Horst Sievert
Director of the CardioVascular Center Frankfurt, chief of the Department of Internal Medicine, Cardiology and Vascular Medicine of the Sankt Katharinen Hospital in Frankfurt, Germany.
Professor of Internal Medicine/Cardiology at the University of Frankfurt.

Dr. Horst Sievert is the Director of the CardioVascular Center Frankfurt, chief of the Department of Internal Medicine, Cardiology and Vascular Medicine of the Sankt Katharinen Hospital in Frankfurt, Germany. He is also a Professor of Internal Medicine/Cardiology at the University of Frankfurt.He hasbeen the principal investigatorof manyclinical trials and has authored more than 300manuscripts and 700 abstracts in peer reviewed journals, 125books and book contributions. He has also delivered more than 3,000lectures around the worldand has organized more than 300 workshops, congresses and conferences.

Lynne W. Stevenson

Dr. Stevenson has been Director of Cardiomyopathy and Heart Failure Programs at UCLA, Brigham and Women’s Hospital, and has recently moved to become Director of Cardiomyopathy at Vanderbilt University. She has been an active member of AHA, ACC, ISHLT, and HFSA societies and a major contributing writer to 30 national guidelines relating to heart failure, cardiac transplantation, ventricular assist devices, arrhythmia de-vices, and decision-making in advanced heart failure, and co-chair of the ACC Expert Consensus Pathway on Risk Assessment, Management, and Clinical Trajectory of Heart Failure Hospitalization, just released in September 2019. Read more

Dr. Wilson Tang
Professor of Medicine at Cleveland Clinic Lerner College of Medicine at Case Western Reserve University

Dr. Tang is Professor of Medicine at Cleveland Clinic Lerner College of Medicine at Case Western Reserve University. He serves as director for Hub Research Capacity for the Clinical and Translational Sciences Collaborative for human mechanistic studiesand the Medical Director for the Cleveland Clinic GeneBank Study. As a clinician-scientist and practicing heart failure/transplant cardiologist specialized in cardiomyopathies and kidney-/cancer-related heart diseases, Dr. Tang’s translational research focuses on understanding the cellular and molecular mechanisms that contribute to disease progression in heart failure and cardio-renal disease. He has been elected as member of the American Society of Clinical Investigation in 2013 for his contributions to mechanistic understanding of cardio-renal syndromes, and the Association of American Physicians in 2018 for studying the contributing role of diet and microbiome in cardiovascular diseases.

Jeffrey Testani
Associate Professor of Medicine (tenure track), Yale University School of Medicine, New Haven, CT

My clinical training is as an advanced heart failure and cardiac transplantation physician with formal research training in patient oriented translational research. My research program is supported by NIH and investigator-initiated industry sources and uses techniques of both translational and clinical research to further the mechanistic understanding of cardiac-renal interactions, fluid and sodium homeostasis, and diuretic resistance in heart failure. The primary approach of my current research program is prospective mechanistic human studies in heart failure patients. Notably, we have enrolled over 700 patients and conducted over 1300 intense biospecimen collections resulting in the approximately 500,000 biospecimens currently housed in our biorepository. Read more

Katherine R. Tuttle, MD, FASN, FACP, FNKF,
Executive Director for Research at Providence Health Care, Co-Principal Investigator of the Institute of Translational Health Sciences and Professor of Medicine at the University of Washington

Dr. Tuttle earned her medical degree and completed her residency in Internal Medicine at Northwestern University School of Medicine in Chicago, Illinois. She was a fellow in Metabolism and Endocrinology at Washington University in St. Louis, Missouri. Her Nephrology fellowship training was performed at University of Texas Health Science Center in San Antonio, Texas. Dr. Tuttle’s major research interests are in clinical and translational science for diabetes and chronic kidney disease. She has published over 250original research contributions and served two terms asAssociate Editor forthe Clinical Journal of the American Society of Nephrology and theAmerican Journal of Kidney Disease. Dr. Tuttle has received many honors and awards including the Medal of Excellence from the American Association of Kidney Patients, Garabed Eknoyan Award from the National Kidney Foundation, the YWCA Woman of Achievement Award in Science, and two OutstandingClinical Faculty Awards at the University of Washington. Dr. Tuttle served on the Board of Directors for the Kidney Health Initiative and has chaired numerouskidney and diabetes related working groups and committees for organizations including the NIDDK/NIH, the National Kidney Foundation, the American Society of Nephrology, the International Society of Nephrology, and the American Diabetes Association.

Stephan von Haehling, MD, PhD, DIC, FESC
consultant cardiologist and Associate Professor of Medicine at the Department of Cardiology and Pneumology at the University Medical Center Göttingen, Germany

Stephan von Haehling, MD, PhD, DIC, FESC is a consultant cardiologist and Associate Professor of Medicine at the Department of Cardiology and Pneumology at the University Medical Center Göttingen, Germany. He obtained his MD at the Institute of Immunology at Charité Medical School, Berlin, Germany. His PhD was awarded by Imperial College, London, UK after he completed studies into inflammatory mechanisms of heart failure at the National Heart and Lung Institute in London. Dr. von Haehling has authored more than 250 original research papers, review articles, and editorials. His research interests include the pathophysiology of heart failure, muscle wasting, sarcopenia, biomarkers, cardio-oncology, and novel treatments.

Matthew Ryan Weir, M.D.
Professor and Director Division of Nephrology
University of Maryland School of Medicine

Matthew R. Weir, M.D. is attending physician and Director of the Division of Nephrology in the Department of Medicine at the University of Maryland Hospital, Baltimore.He is also Professor of Medicine at the University of Maryland School of Medicine.Dr. Weir’s primary research interests include the use of antihypertensive therapy for the treatment of diabetic nephropathy, hypertensive renal injury in African Americans, cardiovascular disease in patients with chronic kidney disease, and mineralocorticoid receptor antagonism to treat atherosclerosis. He has written more than 600 manuscripts and book chapters about these topics.He has edited 8 books on topics in nephrology, transplantation, and hypertension. He has presented at numerous international scientific association meetings, hospitals, and medical schools. Read more

David C Wheeler
Professor of Kidney Medicine at University College London, UKand Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust.

David is Professor of Kidney Medicine at University College London, UKand Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust. He is a clinician scientist interested in the complications of chronic kidney disease, specifically those that increase the burden of cardiovascular disease and/or accelerate progression of kidney failure. He has participated in the development and running of several large-scale clinical trials testing lipid lowering regimens, calcimimetics, SGLT2 inhibitors and HIF stabilisersin patients chronic kidney disease. Other roles include Honorary Professorial Fellow of The George Institute and Chair of the International Society of Nephrology Advancing Clinical Trials network. David has been involved in the development of Clinical Practice Guidelines for several organisations, most recently for Kidney Disease: Improving Global Outcomes (KDIGO).He served as KDIGO co-chair between 2012 and 2019. In the UK, he is National Institute of Health Research (NIHR)Renal Specialty Lead and Co-Medical Director of the North Thames NIHR Clinical Research Network.

Jay B. Wish, MD
Professor of Clinical Medicine at Indiana University School of Medicine in Indianapolis and Chief Medical Officer for Dialysis at Indiana University Health

Jay B. Wish is past president of the National Forum of ESRD Networksand has been an advisor to the Centers for Medicare and Medicaid Services (CMS) on quality improvement issues in dialysis. He served on the Board of Directors of the Renal Physicians Association and the American Association of Kidney Patients and was the recipient of thelatter’s Visionary Award in 2005. Dr. Wish is Vice Chairman of the Editorial Advisory Board for Nephrology News & Issues and on the editorial boards of the Journal of the American Society of Nephrology and Clinical Journal of the American Society of Nephrology. He has had over 100 articles, reviews, and book chapters published, particularly in the areas of ESRD quality oversight/improvement, accountability, anemia management and vascular access.

Prof. Dr. med Jose L. Zamorano
Chief of Cardiology, University Hospital Ramón y CajalMadrid, Spain

ose L. Zamorano is a Professor of Medicine at the University Alcala de Henares, Madrid, and the Chief of Cardiology at the University Hospital Ramón y Cajal.Prof. Zamorano obtainedhis medical degree fromthe University Complutense in 1987 and his doctor in Medicine in 1991.He received his board certification in Cardiology in 1993 beforejoiningas an Associate Professorthe faculty atthe Complutense University. Dr. Zamorano’s has a broad range of research interests includingheart failure, ischaemic heartdisease, cardiovascular risk factors and cardiovascular imaging modalities. Within these fields, Prof. Zamorano has published over 400articles andtwentybooks including the European Textbook of Cardiovascular Imaging.His impact factor is > 1500 and Hirsch Index of 100with more than 15000 citations. Read more

Faiez Zannad, MD, PhD, FESC
Inserm, University of Lorraine, CHRU Nancy, France

Faiez Zannad is Professor of Therapeutics attheUniversity ofLorraine,Head of the Division of Heart Failure and Hypertension,and Director of the Inserm Clinical Investigation Center at Institut Lorrain du Coeur et des Vaisseaux, Nancy, France.He is a cardiologist and heart failure(HF)specialist. After a researchfellowship at the University of Oxford (UK), he went on to complete a PhD in clinical pharmacology (Lyons, France).He is Eugene Braunwald Scholar, visiting Professorat Brigham & Women’s hospital, Harvard Medical School, Boston, USA.He has pioneeredand made significant contributions to research and care in HF, such as evidence-based therapyfor HF(mainly mineralocorticoid receptorantagonistsand beta-blockers, anticoagulants),as well as inmajor comorbid diseases in HF, such as sleep-disordered breathing, autonomic nervous dysfunction, diabetes, hyperkalaemia, chronic kidney diseaseand thrombosis.He recentlyled twoimportantEuropean-granted HF biomarker and fibrosis programmesandis steering several ongoing major HF trials. He successfully implemented thelargest HF disease management programmein France (ICALOR). Read more